This study is in progress, not accepting new patients
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at UCSD UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Laura Rosow (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Laura Rosow (ucsf)
As a member of the Neuromuscular Medicine division, I see patients with a variety of neurological disorders, including: neuropathy, muscle disease (hereditary and acquired myopathies/muscular dystrophies), neuromuscular junction disorders (such as myasthenia gravis), and diseases of the spine and nerve roots.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT06643481
- Phase
- Phase 2 Amyotropic Lateral Sclerosis (ALS) Research Study
- Study Type
- Interventional
- Participants
- About 251 people participating
- Last Updated